Hereditary Cancer Panel denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Hereditary Cancer Panel Testing as Not Medically Necessary

UnitedHealthcare applies specific clinical criteria when evaluating requests for hereditary cancer panel testing. Denials on medical-necessity grounds typically occur when the submitted documentation does not clearly establish that the patient meets UHC's published coverage criteria — which may include personal and family history thresholds, prior cancer diagnoses, or specific tumor characteristics. Because these criteria are updated periodically, always retrieve UHC's current Medical Policy for hereditary cancer testing directly from uhcprovider.com before you appeal.

## Why This Denial Is Appealable

Hereditary cancer panel testing is supported by major professional societies including the National Comprehensive Cancer Network (NCCN), the American Society of Breast Surgeons, and the American College of Medical Genetics and Genomics (ACMG). When a prescribing clinician has determined that testing is medically indicated and documented that determination in the medical record, the denial is contestable on both clinical and procedural grounds.

## Your Federal Appeal Rights

• Internal appeal (Level 1): You have the right to a full-and-fair internal review under ERISA §503 (employer plans) or applicable state law. File within the timeframe stated on your denial letter — typically 180 days.
• External review: After exhausting internal appeals, ACA §2719 entitles most plan members to an independent external review by an accredited Independent Review Organization (IRO). The standard external-review window is approximately four months from the final internal denial. If your situation is urgent — for example, a pending surgery or rapidly progressing family history concern — request expedited external review, which must be decided within 72 hours.

## Concrete Appeal Steps and Timeline

1. Request the complete Explanation of Benefits (EOB) and the specific denial reason code in writing. 2. Obtain UHC's current published Medical Policy for hereditary cancer testing. 3. Have your clinician draft a detailed letter of medical necessity (see documentation below). 4. Submit your Level 1 internal appeal with all supporting records. UHC must decide within 30 days for pre-service and 60 days for post-service appeals. 5. If denied internally, file for external review within the IRO window shown on the denial.

## Documentation to Gather

• Diagnosis confirmation: Pathology reports, oncology notes, or genetic counselor assessment confirming the clinical indication.
• Personal and family history: Documented multi-generational cancer history with relationship, cancer type, and age at diagnosis for each affected relative.
• Prior genetic testing history: Any prior single-gene tests performed, dates, and results — demonstrating why a panel is now clinically indicated.
• Clinical severity: Chart notes describing how the findings increase risk and how the test result will change clinical management.
• Prescriber letter of medical necessity: A specific, signed statement from the ordering physician or genetic counselor explaining why this patient meets UHC's own published criteria.

## Criteria-Mapping Structure

Copy each requirement listed in UHC's Medical Policy into a table. In the adjacent column, cite the exact chart fact, date, and source document that satisfies it. Submit this mapping as a cover sheet. This forces the reviewer to address each criterion individually rather than issue a blanket denial.